Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,212 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Glucose Administration Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Not applicable Interventional Results available

Glucose Control In Hematopoetic Stem Cell Transplant

NCT00582036
View directory record Official record
Conditions
Hyperglycemia, Hematopoietic Stem Cell Transplantation
Interventions
Regular Insulin, Deployment of the MiniMed Paradigm monitoring device
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

NCT03089606
View directory record Official record
Conditions
Melanoma
Interventions
FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab, CT scan
Diagnostic Test · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.

NCT01124864
View directory record Official record
Conditions
Non-small-cell Lung Cancer
Interventions
AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Rockville, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study

NCT05896748
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1)
Interventions
Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Macon, Georgia • Austin, Texas • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

NCT00555750
View directory record Official record
Conditions
Primary Insomnia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 30, 2026, 7:42 PM EDT
Active, not recruiting Phase 2 Interventional

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer

NCT03999710
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer, Nsclc, NSCLC Stage II, NSCLC, Stage III
Interventions
Radiation Therapy, Durvalumab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Withdrawn Not applicable Interventional

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

NCT04140513
View directory record Official record
Conditions
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography
Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

AVACEN Treatment Method and Postprandial Blood Glucose

NCT04018976
View directory record Official record
Conditions
Postprandial Hyperglycemia
Interventions
AVACEN 100, AVACEN 100 heat only, AVACEN 100 sham
Device
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

NCT05035082
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
semaglutide, oral glucose-lowering medications (commercially available)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,018 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

NCT05757791
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Empagliflozin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

NCT00711243
View directory record Official record
Conditions
Gastric Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, fluorouracil, oxaliplatin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial to Assess Efficacy and Safety of Continuous Glucose Monitoring in Children 4-<10 Years With T1DM

NCT00760526
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Continuous glucose monitor, Home blood glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
4 Years to 9 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Stanford, California • New Haven, Connecticut • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

NCT02111850
View directory record Official record
Conditions
Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer
Interventions
Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL), Cyclophosphamide, Fludarabine, Aldesleukin
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Not applicable Interventional

Continuous Glucose Monitoring and Diabetes

NCT05840250
View directory record Official record
Conditions
Diabetes
Interventions
Continuous Glucose Monitoring and Education Support
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Sep 30, 2026, 7:42 PM EDT
Terminated Phase 1 Interventional Results available

Direct Peritoneal Resuscitation in Gastroschisis

NCT03205553
View directory record Official record
Conditions
Gastroschisis
Interventions
SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
Procedure · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 12 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

NCT00066469
View directory record Official record
Conditions
Lymphoproliferative Disorder
Interventions
rituximab, cyclophosphamide, methylprednisolone, prednisone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109
View directory record Official record
Conditions
Metabolic Diseases
Interventions
Oral Glucose Tolerance Test, Kisspeptin, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Sep 30, 2026, 7:42 PM EDT
Not listed Not applicable Interventional

Improving Diabetes Equity and Advancing Care Study

NCT06040463
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support
Behavioral
Lead sponsor
Sinai Health System
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Phase 1 Interventional

Early Blood Pressure Management in Extremely Premature Infants

NCT00874393
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Hypotension, Blood Pressure
Interventions
Dopamine, Hydrocortisone, Infusion Placebo, Syringe Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 24 Hours
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Sep 30, 2026, 7:42 PM EDT
Completed Not applicable Interventional Results available

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

NCT03195140
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Predictive Low Glucose Suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Santa Barbara, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Sep 30, 2026, 7:42 PM EDT